Daryl Richard Sauer

USPTO Granted Patents = 19 (Patent Applications = 3)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 6.2

ph-index = 6

Forward Citations = 99(Granted Patents)

Location History:

Trevor, WI (US) (1999 - 2016)
Abbott Park, IL (US) (2016)

Company Filing History:

8 out of 4,177

Abbott Laboratories Corporation

Abb Vie Deutschland Gmbh & Co. Kg

5. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2016

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9487505 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them (2016-11-08),

2. 9242933 - Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) (2016-01-26),

3. 8895749 - 4-(4-pyridinyl)-benzamides and their use as rock activity modulators (2014-11-25),

4. 8580842 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them (2013-11-12),

5. 8476275 - N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor (2013-07-02),

6. 8445686 - 4-(4-pyridinyl)-benzamides and their use as rock activity modulators (2013-05-21),

7. 8350055 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them (2013-01-08),

8. 8207160 - [object Object] (2012-06-26),

9. 8183250 - Potent PARP inhibitors (2012-05-22),

10. 8114875 - [object Object] (2012-02-14),

11. 7910742 - Survivin inhibitors (2011-03-22),

12. 7902379 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them (2011-03-08),

13. 7592466 - Ureas having antiangiogenic activity (2009-09-22),

14. 7320979 - N-[(piperazinyl)hetaryl]arylsulfonamide compounds (2008-01-22),

15. 6495562 - Naphthamidine urokinase inhibitors (2002-12-17),

Title: The Innovative Journey of Daryl Richard Sauer

Introduction:

Daryl Richard Sauer, a prolific inventor hailing from Trevor, WI (US), has made remarkable contributions to the field of pharmaceuticals and medical treatments. With an impressive portfolio of 19 patents, Sauer's groundbreaking work has helped advance the development of vital medicaments and compounds.

Latest Patents:

Sauer's latest patents include "Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them," which focus on novel compounds as positive modulators of the metabotropic glutamate receptor 2 (mGlu2 receptor). These compounds hold significant promise in the treatment of neurological and psychiatric disorders associated with glutamate dysfunction.

Career Highlights:

Throughout his career, Daryl Richard Sauer has honed his expertise while working at renowned companies such as Abbott Laboratories Corporation and Abbott Gmbh & Co. Kg. His innovative spirit and dedication to scientific advancement have been instrumental in shaping the pharmaceutical landscape.

Collaborations:

Sauer's collaborative efforts with esteemed colleagues like Wilfried Lubisch and Liliane Unger have led to synergistic breakthroughs in the realm of pharmaceutical research. Together, they have pioneered new methodologies and compounds that have the potential to revolutionize medical treatments.

Conclusion:

In conclusion, Daryl Richard Sauer stands as a visionary inventor whose forward-thinking approach has propelled him to the forefront of pharmaceutical innovation. His relentless pursuit of excellence and commitment to enhancing healthcare outcomes epitomize the spirit of creativity and ingenuity in the realm of inventions.

This text is generated by artificial intelligence and may not be accurate.